Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RALOX-HAIC vs FOLFOX-HAIC in Hepatocellular Carcinoma
NCT06519578Recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of raltitrexed in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Renji Hospital. Primary endpoints: Progression-Free Survival at 2 years, Time to Progression at 2 years and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
raltitrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06519578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519578.